Literature DB >> 18712715

A graphical device to represent the outcomes of a logistic regression analysis.

Ries Kranse1, Monique Roobol, Fritz H Schröder.   

Abstract

BACKGROUND: Ongoing research on the best way to diagnose prostate cancer has yielded and will continue to yield vast amounts of information. Based on, for example, information from prostate cancer screening trials models have been made that enable urologists to predict which man has prostate cancer on the basis of pre-biopsy data. In patients with screen detected prostate cancer, the presence of indolent disease can now be identified with reasonable certainty by a different model. For these men active surveillance may be a better option than aggressive treatment with its possible side effects as impotence, incontinence and bowel damage. Both models mentioned above are logistic regression models. Nomograms enable their use in daily clinical practice.
METHODS: Nomograms require the memorization and addition of intermediate results. We aimed to design a device that has the same function as a nomogram without this draw back.
RESULTS: A new device that resembles a circular slide rule was developed and is currently being tested in prostate cancer diagnosis and in prostate cancer patient counseling.
CONCLUSIONS: The new device has identical functionality to the nomogram without the drawback of the latter. The application of the device is not limited to the field of prostate cancer research. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18712715     DOI: 10.1002/pros.20840

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

Review 1.  Prostate cancer nomograms: a review of their use in cancer detection and treatment.

Authors:  R J Caras; Joseph R Sterbis
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

2.  Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.

Authors:  R W Foley; D J Lundon; K Murphy; T B Murphy; D J Galvin; R W G Watson
Journal:  Ir J Med Sci       Date:  2015-04-07       Impact factor: 1.568

3.  Prostate cancer: Rescreening policies and risk calculators.

Authors:  Monique J Roobol
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

4.  Prostate cancer: utility of the risk indicator model in screening.

Authors:  Stacy Loeb; William J Catalona
Journal:  Nat Rev Urol       Date:  2010-04       Impact factor: 14.432

Review 5.  Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.

Authors:  Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

Review 6.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

Review 7.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

8.  Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Authors:  Peter K F Chiu; Monique J Roobol; Jeremy Y Teoh; Wai-Man Lee; Siu-Ying Yip; See-Ming Hou; Chris H Bangma; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-27       Impact factor: 2.370

9.  Patients with Persistently Elevated PSA and Negative Results of TRUS-Biopsy: Does 6-Month Treatment with Dutasteride can Indicate Candidates for Re-Biopsy. What is the Best of Saturation Schemes: Transrectal or Transperineal Approach?

Authors:  Sergey Kravchick; Leonid Lobik; Shmuel Cytron; Yakov Kravchenko; David Ben Dor; Ronit Peled
Journal:  Pathol Oncol Res       Date:  2015-03-10       Impact factor: 3.201

10.  External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.

Authors:  Cédric Poyet; Marian S Wettstein; Dara J Lundon; Bimal Bhindi; Girish S Kulkarni; Karim Saba; Tullio Sulser; A J Vickers; Thomas Hermanns
Journal:  J Urol       Date:  2016-05-14       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.